U.S. stocks mixed; investors digest economic data as Nvidia weighs
LONDON - Consumer health company Haleon plc (LSE/NYSE:HLN) announced Monday that Vindi Banga will succeed Sir Dave Lewis as Chair of the Board, effective January 1, 2026.
Lewis will step down on December 31, 2025, to pursue a new executive role after serving as Chair since Haleon's listing in July 2022.
Banga, who has served as Haleon's Senior Independent Director since the company's listing, was unanimously appointed by the board. He brings 33 years of experience from Unilever plc, where he previously held positions as CEO and Chair of Hindustan Unilever Ltd, and was responsible for Global Home & Personal Care, Foods and Ice Cream as a member of Unilever's Executive Board.
Banga currently serves as Chair of UK Government Investments Limited and has previously held positions as Senior Independent Director at GSK and Marks and Spencer plc. He is also a partner at private investment firm CD&R and Chair of Council of Imperial College London.
"After more than three years Haleon is now well established as an independent listed company," Lewis said in a statement. "My decision to step down is a personal one and is related to a new unique opportunity which I wish to take forward."
Banga stated that it is "a privilege to Chair Haleon" and that he looks forward to "working with the Board and management team to support Haleon's continued development."
Details regarding Banga's remuneration and the appointment of a successor as Senior Independent Director will be announced before his appointment takes effect, according to the company press release statement.
Haleon is a global consumer health company whose portfolio includes brands such as Advil, Centrum, Sensodyne, and Panadol.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.